Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00986206 · ClinicalTrials.gov registry record

Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer

A clinical trial, sponsored by Women and Infants Hospital of Rhode Island.

Completed
Registry status
525
Enrollment target

NCT00986206 is a clinical trial that has completed, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 525 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00986206 has completed, sponsored by Women and Infants Hospital of Rhode Island.

COMPLETED
Registry status
525 participants
Enrollment target

Study Summary

RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer. PURPOSE: This clinical trial is studying using the lysophosphatidic acid assay to see how well it works in early detection of ovarian cancer in patients with ovarian cancer or who are at risk for ovarian cancer.

Interventions

  • DIAGNOSTIC_TEST Biomarker LPA and HE4

Trial Details

FieldValue
Enrollment Target 525 participants
Start Date 2009-06
Est. Completion 2015-07

What the Registry Record Tells You About NCT00986206

The ClinicalTrials.gov registry entry for NCT00986206 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 525 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Women and Infants Hospital of Rhode Island, which has 65 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Biomarker LPA and HE4 is the first listed.

NCT00986206 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00986206 about?

NCT00986206 is a clinical study titled "Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer". RATIONALE: Screening tests, such as the lysophosphatidic acid assay, may help doctors find cancer cells early and plan better treatment for ovarian cancer. PURPOSE: This clinical trial is studying using the lysophosphatidic acid assay to see how well it works in early detection of ovarian cancer in...

What is the current status of trial NCT00986206?

This trial is currently completed. The enrollment target is 525 participants. The study started on 2009-06. Estimated completion is 2015-07.

What interventions are being tested in trial NCT00986206?

The interventions under investigation include: Biomarker LPA and HE4 (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT00986206?

This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.